PASG RSI Chart
Last 7 days
-8.2%
Last 30 days
6.3%
Last 90 days
4.7%
Trailing 12 Months
38.1%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2022 | 0 | 985.0K | 1.6M | 2.3M |
2021 | 0 | 0 | 0 | 343.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 13, 2024 | borthwick kathleen | sold | -1,425 | 0.97 | -1,470 | svp, interim cfo |
Feb 13, 2024 | forman mark s | sold | -1,588 | 0.97 | -1,638 | chief medical officer |
Feb 10, 2024 | borthwick kathleen | acquired | - | - | 4,000 | svp, interim cfo |
Feb 10, 2024 | forman mark s | acquired | - | - | 5,000 | chief medical officer |
Jan 02, 2024 | cale edgar b. | sold | -14,389 | 0.91 | -15,813 | gc & corporate secretary |
Jan 02, 2024 | borthwick kathleen | sold | -9,711 | 0.91 | -10,672 | svp, interim cfo |
Jan 02, 2024 | forman mark s | sold | -14,389 | 0.91 | -15,813 | chief medical officer |
Dec 31, 2023 | borthwick kathleen | acquired | - | - | 30,000 | svp, interim cfo |
Dec 31, 2023 | forman mark s | acquired | - | - | 50,000 | chief medical officer |
Dec 31, 2023 | cale edgar b. | acquired | - | - | 50,000 | gc & corporate secretary |
Which funds bought or sold PASG recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | Royal Bank of Canada | added | 31.93 | 1,000 | 1,000 | -% |
May 15, 2024 | CITADEL ADVISORS LLC | reduced | -28.92 | -15,735 | 299,095 | -% |
May 15, 2024 | STATE STREET CORP | unchanged | - | 42,117 | 167,229 | -% |
May 15, 2024 | MORGAN STANLEY | unchanged | - | 4,704 | 18,679 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | reduced | -96.88 | -31.00 | 1.00 | -% |
May 15, 2024 | BARCLAYS PLC | unchanged | - | 5,000 | 18,000 | -% |
May 15, 2024 | Federation des caisses Desjardins du Quebec | new | - | 28.00 | 28.00 | -% |
May 15, 2024 | Scientech Research LLC | sold off | -100 | -19,042 | - | -% |
May 15, 2024 | Cubist Systematic Strategies, LLC | new | - | 15,242 | 15,242 | -% |
May 15, 2024 | Lynx1 Capital Management LP | added | 1,178 | 6,158,980 | 6,541,930 | 1.70% |
Unveiling Passage Bio Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Passage Bio Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Passage Bio Inc News
Income Statement (Quarterly) | |||||||
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2021Q4 | 2021Q3 | 2021Q2 |
Revenue | 42.2% | 1,173,000 | 825,000 | 270,000 | 228,000 | 186,000 | 99,000 |
S&GA Expenses | -0.7% | 10,587,000 | 10,664,000 | 12,991,000 | 17,192,000 | 14,978,000 | 15,422,000 |
Net Income | -1.4% | -27,071,000 | -26,701,000 | -39,542,000 | -51,154,000 | -46,915,000 | -48,435,000 |
Net Income Margin | 39.1% | -59.99 | -98.47 | -183 | -540 | - | - |
Free Cashflow | -2.7% | -24,021,000 | -23,395,000 | -26,083,000 | -30,775,000 | -41,056,000 | -24,330,000 |
Balance Sheet | ||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2018Q4 |
Assets | -6.7% | 141 | 151 | 169 | 194 | 213 | 244 | 270 | 299 | 333 | 355 | 391 | 440 | 465 | 328 | 359 | 378 | 392 | 179 | 33.00 |
Current Assets | -8.2% | 108 | 118 | 136 | 154 | 172 | 197 | 223 | 251 | 283 | 325 | 366 | 419 | 451 | 317 | 350 | 368 | 382 | 166 | 33.00 |
Cash Equivalents | 69.4% | 37.00 | 22.00 | 34.00 | 30.00 | 33.00 | 35.00 | 63.00 | 91.00 | 102 | 129 | 163 | 215 | 250 | 135 | 201 | 353 | 367 | 159 | 25.00 |
Net PPE | -5.3% | 14.00 | 15.00 | 16.00 | 20.00 | 22.00 | 23.00 | 23.00 | 24.00 | 24.00 | 24.00 | 18.00 | 13.00 | 7.00 | 3.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 |
Liabilities | -9.2% | 36.00 | 39.00 | 43.00 | 43.00 | 43.00 | 42.00 | 46.00 | 51.00 | 52.00 | 36.00 | 29.00 | 37.00 | 24.00 | 23.00 | 20.00 | 15.00 | 6.00 | 4.00 | 3.00 |
Current Liabilities | -21.4% | 13.00 | 16.00 | 20.00 | 20.00 | 17.00 | 18.00 | 22.00 | 27.00 | 27.00 | 29.00 | 22.00 | 31.00 | 19.00 | 21.00 | 19.00 | 14.00 | 5.00 | 4.00 | 0.00 |
Shareholder's Equity | -5.8% | 105 | 111 | 126 | 150 | 170 | 201 | 224 | 248 | 281 | 319 | 362 | 402 | 442 | 305 | 339 | 363 | 387 | - | - |
Retained Earnings | -2.8% | -611 | -594 | -577 | -550 | -526 | -492 | -465 | -438 | -399 | -356 | -305 | -258 | -209 | -170 | -131 | -103 | -76.20 | -58.66 | -13.03 |
Additional Paid-In Capital | 1.5% | 716 | 706 | 704 | 701 | 698 | 695 | 691 | 688 | 682 | 675 | 667 | 660 | 651 | 476 | 471 | 467 | 463 | 2.00 | 1.00 |
Shares Outstanding | 12.1% | 62.00 | 55.00 | 55.00 | 55.00 | 55.00 | 55.00 | 54.00 | 54.00 | 54.00 | 54.00 | 53.00 | 54.00 | - | - | - | - | - | - | - |
Float | - | - | - | - | 47.00 | - | - | - | 101 | - | - | - | 483 | - | - | - | 772 | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 3.0% | -18,929 | -19,516 | -19,163 | -17,139 | -22,446 | -24,021 | -23,395 | -26,083 | -44,711 | -30,775 | -41,056 | -24,330 | -30,718 | -29,424 | -17,530 | -11,715 | -21,851 | -17,478 | -11,424 | -10,780 | -214 |
Share Based Compensation | 1.6% | 1,595 | 1,570 | 2,824 | 3,743 | 2,784 | 3,477 | 2,862 | 6,278 | 6,337 | 7,575 | 6,815 | 8,561 | 9,740 | 4,324 | 4,033 | 3,855 | 2,368 | 1,036 | 95.00 | 92.00 | 231 |
Cashflow From Investing | 232.3% | 25,251 | 7,600 | 22,451 | 13,969 | 21,217 | -3,358 | -4,758 | 16,004 | 17,311 | -3,605 | -11,555 | -10,257 | -20,397 | -36,546 | -135,367 | -94.00 | -99.00 | -43.00 | -109 | -657 | -884 |
Cashflow From Financing | 18904.3% | 8,742 | 46.00 | - | - | - | -588 | -408 | -406 | 49.00 | 455 | 44.00 | 523 | 165,634 | 402 | 44.00 | -1,596 | 229,904 | -799 | 109,938 | 46,306 | 20,157 |
Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development | $ 11,535 | $ 16,836 |
General and administrative | 6,515 | 19,047 |
Loss from operations | (18,050) | (35,883) |
Other income (expense), net | 1,339 | 1,545 |
Net loss | $ (16,711) | $ (34,338) |
Per share information: | ||
Net loss per share of common stock, basic | $ (0.30) | $ (0.63) |
Net loss per share of common stock, diluted | $ (0.30) | $ (0.63) |
Weighted average common shares outstanding, basic | 56,295,540 | 54,618,799 |
Weighted average common shares outstanding, diluted | 56,295,540 | 54,618,799 |
Comprehensive loss: | ||
Net loss | $ (16,711) | $ (34,338) |
Unrealized gain (loss) on marketable securities | (26) | 539 |
Comprehensive loss | $ (16,737) | $ (33,799) |
Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 36,773 | $ 21,709 |
Marketable securities | 67,752 | 92,585 |
Prepaid expenses and other current assets | 1,784 | 923 |
Prepaid research and development | 1,984 | 2,742 |
Total current assets | 108,293 | 117,959 |
Property and equipment, net | 14,489 | 15,295 |
Right of use assets - operating leases | 17,087 | 16,858 |
Other assets | 662 | 433 |
Total assets | 140,531 | 150,545 |
Current liabilities: | ||
Accounts payable | 1,687 | 1,298 |
Accrued expenses and other current liabilities | 7,483 | 11,670 |
Operating lease liabilities | 3,671 | 3,373 |
Total current liabilities | 12,841 | 16,341 |
Operating lease liabilities - noncurrent | 22,807 | 22,921 |
Total liabilities | 35,648 | 39,262 |
Commitments and contingencies (note 9) | ||
Stockholders' equity: | ||
Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding at both March 31, 2024 and December 31, 2023 | ||
Common stock, $0.0001 par value: 300,000,000 shares authorized; 61,611,796 shares issued and outstanding at March 31, 2024 and 54,944,130 shares issued and outstanding at December 31, 2023 | 6 | 5 |
Additional paidin capital | 716,125 | 705,789 |
Accumulated other comprehensive income (loss) | (69) | (43) |
Accumulated deficit | (611,179) | (594,468) |
Total stockholders' equity | 104,883 | 111,283 |
Total liabilities and stockholders' equity | $ 140,531 | $ 150,545 |